Last $99.07 USD
Change Today +0.01 / 0.01%
Volume 972.2K
NVS On Other Exchanges
Symbol
Exchange
Xetra
New York
OTC US
Mexico
SIX Swiss Ex
SIX Swiss Ex
Frankfurt
As of 2:35 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-sponsored adr (NVS) Snapshot

Open
$98.39
Previous Close
$99.06
Day High
$99.22
Day Low
$97.69
52 Week High
02/9/15 - $103.50
52 Week Low
03/20/14 - $80.64
Market Cap
268.1B
Average Volume 10 Days
1.1M
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
03/2/15
P/E TM
--
Dividend
$2.82
Dividend Yield
2.84%
Current Stock Chart for NOVARTIS AG-SPONSORED ADR (NVS)

novartis ag-sponsored adr (NVS) Related Businessweek News

View More BusinessWeek News

novartis ag-sponsored adr (NVS) Details

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company’s Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

133,413 Employees
Last Reported Date: 01/27/15
Founded in 1895

novartis ag-sponsored adr (NVS) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.6.1M
Chief Financial Officer
Total Annual Compensation: SFr.2.6M
President of Institutes for Biomedical Resear...
Total Annual Compensation: $3.0M
Global Head of Novartis Business Services and...
Total Annual Compensation: SFr.1.2M
Division Head of Novartis Pharmaceuticals
Total Annual Compensation: $3.9M
Compensation as of Fiscal Year 2014.

novartis ag-sponsored adr (NVS) Key Developments

Novartis Announces Health Canada's Approval of CosentyxTM (Secukinumab)

Novartis announced that Health Canada has approved CosentyxTM (secukinumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy3. Offering a new treatment option for Canadians living with plaque psoriasis, CosentyxTM is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A1,2.

Novartis Approves Dividend, Payable on March 5, 2015; Announces Board Changes

Novartis at its AGM held on February 27, 2015, approved the  eighteenth consecutive  dividend increase  per share since  the creation of Novartis in 1996, with  an increase of 6% to CHF 2.60 for 2014 compared  to CHF 2.45 in  2013. Payment for the  2014 dividend will be made  with effect from March 5, 2015. The company announced that shareholders elected  Nancy  C. Andrews,  M.D., Ph.D.,  as a  new member  of the Board. Ulrich Lehner, Ph.D. decided not to seek another term of office keeping Board membership to 11 members.

Novartis AG Gets Recommendation for EU Approval for Lung Cancer Drug

Novartis AG announced that it got a positive opinion from the European Medicines Agency's advisory board for its lung cancer drug, Zykadia. Separately, the company said its shareholders approved all resolutions proposed by its board at its annual general meeting. If approved in the European Union (EU), Zykadia will be the first treatment option to address an unmet medical need for patients with ALK+ NSCLC previously treated with crizotinib.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $99.04 USD -0.02

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $103.23 USD +0.44
Johnson & Johnson $101.56 USD -0.78
Merck & Co Inc $58.06 USD -0.283
Pfizer Inc $34.64 USD +0.075
Roche Holding AG SFr.260.20 CHF +0.20
View Industry Companies
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 23.7x
Price/Sales 4.6x
Price/Book 3.5x
Price/Cash Flow 27.1x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.